Chemotherapy and combined modality treatment in Hodgkin's disease.
Several issues in the management of Hodgkin's disease remain to be resolved. These include 1) the most appropriate and effective first-line therapy for advanced disease, 2) the best approach to management of bulky mediastinal disease, 3) the management of uncommon presentations such as subdiaphragmatic disease, and 4) the best approach to salvage therapy for the patient with relapsed or refractory disease. Despite several years of clinical research and several significant advances in the treatment of this disease, the most effective treatment with the minimum amount of acute and delayed toxicity remains to be defined for several subsets of patients. This article reviews recent publications addressing these issues.
Gaynor
E R
ER
Loyola University Stritch School of Medicine, Maywood, Illinois.
Fisher
R I
RI
D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D000206:Actuarial Analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000453:epidemiology; D008479:Mediastinal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D009378:Neoplasms, Multiple Primary / Q000453:epidemiology; D010166:Palliative Care; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis